The first patient in England has been treated with a personalized bowel cancer vaccine, as part of a clinical trial carried out as part of the NHS England project. Cancer vaccine launch platform.
THE launching rampcreated in partnership with Genomics Englandis a platform that aims to accelerate access to clinical trials of personalized cancer vaccines based on messenger ribonucleic acid (mRNA) for people diagnosed with cancer.
Through the platform, people with cancer who are receiving treatment in the NHS in England can be assessed to see if they might be eligible to take part in a clinical trial of a cancer vaccine, and then referred to a hospital which is conducting A try.
To date, 30 hospitals in England have signed up to the Cancer Vaccine Launch Pad and more sites are expected to join the platform, according to a report. NHSE Announcementpublished on May 31, 2024.
The collaboration aims to provide up to 10,000 patients with personalized cancer treatments in the UK by 2030.
Amanda Pritchard, chief executive of the NHS, said: “The NHS is in a unique position to carry out this type of cutting-edge research on a global scale, and as more and more of these trials are launched and carried out in hospitals across the country, our national match-creation of services will ensure that as many eligible patients as possible have the opportunity to access them.
Elliot Phebve, the first patient to be treated under the launch pad initiative, received a developmental vaccine for his bowel cancer at University Hospitals Birmingham NHS Foundation Trust, one of several sites participating in the program. BioNTech-sponsored colorectal cancer vaccine trial.
Experimental cancer vaccines jointly developed by biopharmaceutical companies BioNTech and Genentech, a member of the Roche group, are still in trials and have not yet been approved by regulators.
In 2023, the the government signed an agreement with BioNTechto provide up to 10,000 patients with precision cancer immunotherapies by 2030.
Ultimately, it is expected that the launch pad will be expanded to work with more pharmaceutical industry partners, thereby increasing the number of patients who can participate in a vaccine trial and the types of cancer studied.
Professor Peter Johnson, national clinical director for cancer at the NHS, said: “Access to clinical trials could provide another option for patients and their families, and I am delighted that through our national launchpad we We will expand opportunities to be part of these trials to many more people, and thousands of patients are expected to be recruited over the next year.